|Bid||94.70 x 1100|
|Ask||95.56 x 800|
|Day's Range||94.32 - 97.65|
|52 Week Range||84.38 - 220.20|
|Beta (5Y Monthly)||2.24|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 26, 2021 - Nov 01, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||162.94|
Intellia's (NTLA) investigational gene-editing therapy, NTLA-2001, gets Orphan Drug tag from the FDA for ATTR amyloidosis.
Any biotech acquisition is a good one -- at the right price, of course.
CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.